Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bortezomib + GO-203-2C|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bortezomib||Velcade||Velcade (bortezomib) is a reversible proteasome inhibitor that inhibits survival of malignant cells and regulates bone remodeling (PMID: 26579531). Velcade (bortezomib) is FDA approved for the treatment of mantle cell lymphoma and multiple myeloma (FDA.gov).|
|GO-203-2C||GO-203-2C is a small peptide that binds to mucin (MUC1) at cell membrane, thereby blocking mucin homodimerization and downstream signaling, which leads to antitumor effects (PMID: 26267657).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02658396||Phase I||Bortezomib + GO-203-2C||GO-203-2C + Bortezomib For Relapsed Or Refractory MM||Withdrawn||USA||0|